Medline: 2909443

Gynecologic Oncology 32(1): 1-3, 1989.

Tamoxifen therapy in advanced/recurrent endometrial carcinoma.

Quinn MA, Campbell JJ


Forty-nine patients with advanced/recurrent endometrial carcinoma were treated with Tamoxifen, 20 mg, twice daily. There were six complete and four partial responses (response rate = 20%). The median survival of responders was 34 months compared to 6 months in nonresponders. Toxicity was minimal.

This is a service of:

Uni Logo

Rheinische Friedrich- Wilhelms- Universität Bonn
Medical Center

Dr. G. Quade